Talha Badar: ASH24 abstract in acute leukemia and MDS

Talha Badar, Hematology/Oncology specialist in Mayo Clinic, shared on X:

“ASH24 abstract in acute leukemia and MDS

970 Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial

Summary:

VEN-DEC non-inferior to intensive chemotherapy.

VEN-DEC associated with lower infection rates and duration of cytopenia

VEN-DEC may be better in adverse risk or epigenetic modifier mutations.

IA may be better in favorable risk AML.

Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

Summary:

-Compared to Mido, Gilt improved cCRrates.
-FLT3 ITD allelic burden, NPM1m, WBC, Hb impacted cCR in MVA.
-Most of the pts post consolidation in Gilt arm achieved FLT3 MRD –ve.
-More studies are needed to predict time and type of MRD testing.
Longer follow up for survival.

A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial

Summary:

The triplet combo, improves responses and survival.

FN and lower grade GI AEs were more seen in triplet combination.

25% received > 12 cycles.

Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Summary:

No DLTs or Zifto associated QTc prolongation were reported.

DS occurred in 2% (n=1 Gr 3), managed with supportive care.

High response rates achieved with triplet induction.

Prospective Study of Avapritinib in Patients with Relapsed/Refractory or MRD-Positive Core-Binding Factor Acute Myeloid Leukemia with KIT Mutations

Summary:

In MRD +, ORR was 60.7% and MRD –ve 42.9%

Main AEs were myelosuppression.

Randomized trial needed to further evaluate efficacy in CBF-AML.

Early Versus Late Onset of ESA in Lower Risk Anemic MDS Patients: Results of the GFM Randomized Phase III EPO-PretarTrial

Summary:

Did not delay the time to RBC TD from inclusion.

Increased HI-E and duration of response

Had no effect on PFS, OS or quality of life

Combining ESA and Luspatercept in Non-RS MDS Patients Having Failed ESA – Results of the Phase 1-2 Part a of the GFM Combola Study

Summary:

Difficult to treat LR-MDS with high transfusion burden.

Luspatercept 1.75 mg/kg/3 weekly + EPO 60, 000 weekly chosen for RP2D.

1/3 achieved HI-E.

The combo is being compared to luspatercept alone in PII study.

Results from a Phase 1 Open-Label Dose Escalation and Expansion Trial of Oral Azacitidine + Cedazuridine (ASTX030) in Patients with Myelodysplastic Syndromes (MDS) and MDS/Myeloproliferative Neoplasms (MPN)

Oral azacitidine with cedazuridine showed to have comparable safety and efficacy to parenteral AZA.

Ease of administration of oral agent.

Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the GIMEMA ALL2820

Summary:

Ponatinib? Blina improved responses compare to D-ALBA.

> 95% 12 months OS.

SAEs: leading to interruption or discontinuation were rare and mostly observed in elderly.

Duration of TKI therapy in Ph+ALL needs to determined.

Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial

Summary:

V-HAG regimen achieved 100% CR/CRi in ND ETP-ALL after C1.

Older age associated with inferior survival.

PIII trial has started enrolling.”

Dr. Talha Badar, MD, is a specialist in Hematology Oncology based in Mayo Clinic, Jacksonville, Florida. His primary areas of expertise include Leukemia, particularly Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplantation. Over his career, he has actively contributed to clinical research and clinical trials.

Further Reading:

Highlights from ASH24 Day 1

Highlights from ASH24 Day 2

Highlights from ASH24 Day 3

Highights from ASH24 Day 4

Best of ASH24